Clinical trial
A Multicentre, Open-Label, Exploratory Phase Ib Clinical Study to Assess Safety and Efficacy of an EGFR Tyrosine Kinase Inhibitor in Combination With EGF Pathway Targeting Immunisation (EGF-PTI) in Treatment-Naïve Patients With EGFR Mutant NSCLC. The EPICAL Study
NCT03623750 is registered in ClinicalTrials.gov with Instituto Oncológico Dr Rosell as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Open-Label, Exploratory Phase Ib Clinical Study to Assess Safety and Efficacy of an EGFR Tyrosine Kinase Inhibitor in Combination With EGF Pathway Targeting Immunisation (EGF-PTI) in Treatment-Naïve Patients With EGFR Mutant NSCLC. The EPICAL Study
- Lead sponsor
- Instituto Oncológico Dr Rosell
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- July 6, 2018
- Completion date
- December 14, 2021
- Enrollment
- 23 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.